Profile Previews

Get a glimpse into our company and investor data—powered by the PitchBook Platform

Syndax

Syndax
2005 FOUNDED
PUBLIC STATUS
31-40 EMPLOYEES
SNDX STOCK SYMBOL
$8.64 SHARE PRICE (As of Friday Closing)
Description

Syndax Pharmaceuticals Inc is a clinical stage biopharmaceutical company focused on developing a pipeline of combination therapies in multiple cancer indications. The company's product candidate are entinostat which has direct effects on both cancer cells and immune regulatory cells, and SNDX-6352, an anti-CSF-1R monoclonal antibody, to enhance the body's immune response on tumors that have shown sensitivity to immunotherapy. Business activity of the group is primarily functioned through the region of United States.

Website
Ownership Status
Publicly Held
Financing Status
Formerly VC-backed
Primary Industry
Drug Discovery
Stock Exchange
NAS
Primary Office
  • 400 Totten Pond Road
  • Suite 110
  • Waltham, MA 02451
  • United States

+1 (781) 000-0000
Request full access to PitchBook

You’re viewing a free company profile from the PitchBook Platform. To explore Syndax’s full profile, request a free trial.

Syndax Stock Performance

52 wk Range Market Cap Prev. Close EPS Average Volume Shares
$3.39 - $9.28 $234M $8.78 -$2.65 186K 27.1M

Syndax Financials Summary

In Thousands,
USD
TTM
31-Mar-2019
FY 2018
31-Dec-2018
FY 2017
31-Dec-2017
FY 2016
31-Dec-2016
Enterprise Value 61,342 (19,454) 108,326 370,301
Revenue 1,516 1,517 2,108 1,220
EBITDA (70,784) (75,825) (62,147) (45,339)
Net Income (68,865) (73,961) (60,802) (44,472)
Total Assets 99,392 83,938 137,186 109,013
Total Debt 1,355
Public Fundamental Data provided by Morningstar, Inc. disclaimer

Syndax Valuation and Funding

Deal Type Date Amount Post-Val Valuation/
EBITDA
Debt Status

This information is reserved for PitchBook Platform users. To explore Syndax‘s full profile, request access.

Request full access to PitchBook

Syndax Cap Table

Stock # of Shares
Authorized
Par Value Dividend Rate (%) Original
Issue Price
Liquidation Liquidation
Pref. Multiple
Conversion
Price
% Owned

This information is reserved for PitchBook Platform users. To explore Syndax‘s full profile, request access.

Request full access to PitchBook
To view this company’s complete Cap Table, request access »

Syndax Competitors (28)

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
Affimed Therapeutics Formerly VC-backed Heidelberg, Germany 000 00000 00000000000 00000
00000000 Formerly VC-backed Alameda, CA 000 00000 0&0
00000 Formerly VC-backed Cambridge, MA 000 00000 0&0
000000 00000000000 Failed Transaction (M&A) Cambridge, MA 000 00000 000000&0
00000 000000000 Formerly VC-backed Boulder, CO 000 00000 000000&0 00000
To view this company’s complete list of competitors, request access »

Syndax Investors

Investor Name Investor Type Holding Participating Rounds Investor Since Board Seat Contact Info

This information is reserved for PitchBook Platform users. To explore Syndax‘s full profile, request access.

Request full access to PitchBook

Syndax Executive Team (19)

Name Title Board
Seat
Contact
Info
Briggs Morrison MD Board of Director & Chief Executive Officer
Michael Metzger Chief Operating Officer & President
Richard Shea Chief Financial Officer
Peter Ordentlich Ph.D Chief Technology Officer & Co-Founder
Robert Goodenow Ph.D Chief Business Officer and Secretary

6 Former Executives

You’re viewing 5 of 19 executives. Get the full list »

Syndax Board Members (13)

Name Representing Role Since Contact
Info
Arthur Pappas Pappas Capital Board Member 000 0000
Briggs Morrison MD Syndax Board of Director & Chief Executive Officer 000 0000
George Sledge Jr. Self Director 000 0000
Kim Kamdar Ph.D Domain Associates Board Member 000 0000

9 Former Board Members

You’re viewing 4 of 13 board members. Get the full list »